



**World Health  
Organization**

INN Working Document 24.604  
10/10/2024

**Addendum\* to  
"The use of stems in the selection of International  
Nonproprietary Names (INN) for pharmaceutical  
substances, 2024"**

**ISBN 9-789240-099388**

***Programme on International Nonproprietary Names (INN)***

***Health Products Policy and Standards (HPS)  
Access to Medicines and Health Products (MHP)***

***World Health Organization, Geneva***

© World Health Organization 2024 - All rights reserved. The contents of this document may not be reviewed, abstracted, quoted, referenced, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means, without explicit prior authorization of the WHO INN Programme.

This document contains the collective views of the INN Expert Group and does not necessarily represent the decisions or the stated policy of the World Health Organization.

**Addendum\* to "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" - ISBN 9-789240-099388**

\* This addendum is a cumulative list of all new stems selected by the INN Expert Group since the publication of "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" 2024.

<b>-ampator</b>	<b><math>\alpha</math>-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulators</b> farampator (92), mibampator (103), osavampator (129), pesampator (126), tulrampator (116)
<b>-cirnon</b>	<b>CC chemokine receptor (CCR) antagonists</b> ilacirnon (123), lazucirnon (123), tivumecirnon (128), vercirnon (107), zelnecirnon (130)
<b>-protafib</b>	<b>protein tyrosine phosphatase (HPTP) inhibitors</b> batoprotafib (127), ertiprotafib (87), migoprotafib (128), osunprotafib (129), razuprotafib (116), tegeprotafib (129), vociprotafib (127)
<b>-rogant</b>	<b>retinoic acid receptor-related orphan receptor gamma (ROR<math>\gamma</math>) antagonists and inverse agonists</b> bevurogant (125), cedirogant (123), izumerogant (128), retezorogant (126), vimirogant (120)
<b>-turev</b>	<b>under the advanced therapy scheme for: oncolytic viruses</b> canerpaturev (117), gebasaxturev (126), lerapolturev (125), linoserpaturev (131), suratadenoturev (123), tasadenoturev (117), teserpaturev (119) under (c) category: enadenotucirev (111)
<b>-vatein</b> <b>-covatein</b>	<b>protein vaccine substances</b> <b>coronavirus</b> carocovatein (128), enlicovatein (128), laricovatein (128), riticovatein (128), tibrecovatein (128) -alsecovatein (128), mivalsecovatein (131), upsalcovatein (129) -selvacovatein (128), damlecovatein (131) -sorimcovatein (128), <i>pesorimcovatein</i> (130), <i>tisorimcovatein</i> (130)
<b>-vir</b> <b>-trelvir</b>	<b>antiviral 3CL protease inhibitors</b> abimtrelevir (126), atilotrelvir (129), bofutrelvir (127), deunirmatrelvir (129), ensitrelvir (126), ibuzatrelvir (129), imocitrelvir (130), iscartrelvir (130), limnetrelvir (130), lufotrelvir (125), nirmatrelvir (126), olgotrelvir (129), pomotrelvir (127), zevotrelvir (129)

\*\*\*\*\*

**Amendments were also made in the following stems' definitions:**

**-cyanine**

from *indocyanine fluorescence dye group*

to *cyanine dyes and their derivatives, diagnostic imaging agents*

**-ilide**

from *class III antiarrhythmics, sematilide derivatives*  
to *class III antiarrhythmics, ~~sematilide derivatives~~*

**-kalim**

from *potassium channel activators, antihypertensives.*  
to *potassium channel activators, antihypertensives.*

**-(o)nidine**

from *antihypertensives, clonidine derivatives*  
to  *$\alpha_2$  adrenoreceptor agonists*

under *-rsen*

**-dirsen**

From *targeting muscular dystrophies*  
To *splice-switching oligonucleotides, muscular dystrophies*

under *-tant*

**-netant**

from *neurokinin NK3 receptor antagonists*  
to *neurokinin NK3 and dual NK3-NK1 receptor antagonists*

**-tirom(e)** (future use of final (e) is discouraged to avoid conflict with -terone stem)

from *antihyperlipidemic, thyromimetic derivatives*  
to *antihyperlipidemie, thyromimetic derivatives*

Amendments were also made in the stem's infix:

**-gromab (under -mab)**

from *-gros~~m~~mab*

for the designation of INN for monoclonal antibodies targeting skeletal muscle mass related growth factors and receptors

**-ki- (under -mab)**

for the designation of INN for monoclonal antibodies targeting interleukins,  
to cytokine and cytokine receptors

**Please note that a new naming scheme for monoclonal antibodies** was adopted at the 73<sup>rd</sup> INN Consultation. The document can be retrieved here after and from our webpages at:

[https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-\(inn\)/new\\_mab\\_nomenclature-2021.pdf?sfvrsn=207e78cb\\_12&download=true](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/new_mab_nomenclature-2021.pdf?sfvrsn=207e78cb_12&download=true)